美股新聞 標題聯播 · 近 24 小時 337 則 · 29 個來源 · 最新 9/20 04:53
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · MPLT近 30 天 1 則 · 第 1 / 1 頁
- IPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target?
- AstraZeneca scores in lung cancer; Sandoz inks a China deal
- MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
- MapLight Therapeutics Launching $150 Million Private Placement Financing
- MapLight Therapeutics Announces $150 Million Private Placement Financing
- MapLight CEO on what investors missed in the biotech’s schizophrenia data
- MapLight Therapeutics stock crashes on Phase II schizophrenia data
- Top Midday Decliners
- MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia
- Is MapLight Therapeutics (MPLT) Fully Valued As Its Shares Hold Near $36.56?
- Sector Update: Healthcare Stocks Rise Late Afternoon
- Shopify downgraded, Five Below upgraded: Wall Street's top analyst calls
- Is MapLight Therapeutics, Inc. (MPLT) Stock a Biotech Opportunity Ahead of the ZEPHYR Trial Readout?
- MapLight Therapeutics Announces Changes to Board of Directors
- MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。